Vanderbilt-ingram Cancer Center
Clinical trials sponsored by Vanderbilt-ingram Cancer Center, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can freezing kill lung cancer? new study tests cryodevitalization Results expected Dec 2026 (estimated)
- AI could help avoid unnecessary lung procedures Results expected Jan 2027 (estimated)
- 4,000 volunteers help scientists hunt lung cancer clues in body fluids Results expected Jan 2027 (estimated)
- New drug combo aims to outsmart resistant leukemia Results expected Feb 2027 (estimated)
- Scientists create massive breast tissue library to unlock cancer secrets Results expected Mar 2027 (estimated)
-
Can a targeted drug boost hormone therapy against breast cancer?
Disease control CompletedThis trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Tailored smoking treatment shows promise for vulnerable patients
Disease control CompletedThis study tested a personalized approach to help people quit smoking by matching medication to their nicotine metabolism. 606 adults on Medicaid or Medicare who smoked daily took part. The goal was to see if tailoring treatment improves quit rates.
Phase 3 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
A pill that could block stomach cancer before it starts
Prevention CompletedResearchers are testing whether a drug called eflornithine can reduce DNA damage in stomach cells that have precancerous changes. The trial enrolls adults aged 30 to 60 with atrophic gastritis or intestinal metaplasia, conditions that raise stomach cancer risk. Participants take …
Phase 2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Keto diet plus breast cancer drug shows promise in small study
Symptom relief CompletedThis early-phase study tested whether a 2-week very low-carbohydrate (ketogenic) diet combined with the drug letrozole is feasible and tolerable for people with early-stage estrogen receptor-positive (ER+) breast cancer. 31 postmenopausal women participated before surgery. The go…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Lung nodule biopsy showdown: which method wins?
Knowledge-focused CompletedThis study looked at 288 people with a lung nodule to see which biopsy method works better: CT-guided biopsy (needle through the chest wall) or navigation bronchoscopy (a tube through the airways). The goal was to find which approach gives a clear diagnosis with fewer side effect…
Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC